List Title | APhA DrugInfoLine

Cardiology

SORT BY: Most Recent Most Viewed

April 24, 2017

Risk of CV events reduced with a PCSK9 inhibitor

READ

PREVIEW
Addition of evolocumab (Repatha—Amgen) to statin background therapy in patients with a history of atherosclerotic cardiovascular disease (ASCVD) resulted in significant reductions in LDL...
April 17, 2017

Statin intolerance increases risk of recurrent cardiac events

READ

PREVIEW
Statin intolerance in patients who have had a myocardial infarction (MI) resulted in an increased risk of recurrent MIs and coronary heart disease (CHD) events compared with patients who were...
April 11, 2017

Guidance on periprocedural anticoagulation in patients with atrial fibrillation

READ

PREVIEW
The American College of Cardiology (ACC) released an expert consensus decision pathway on the periprocedural management of anticoagulation in patients with nonvalvular atrial fibrillation (AF)...
March 14, 2017

Evaluating apixaban as an option for patients with severe renal impairment

READ

PREVIEW
No significant differences were observed in rates of major bleeding, composite bleeding, or stroke with use of apixaban (Eliquis—Bristol-Myers Squibb) compared with warfarin in patients with...
February 14, 2017

Administration of ACE inhibitors or ARBs on the day of noncardiac surgery may be harmful

READ

PREVIEW
Withholding ACE inhibitors or angiotensin II receptor blockers (ARBs) within 24 hours of noncardiac surgery was associated with a lower risk of death and postoperative vascular events compared...

Pages

Medication Monitor

RSS Follow Medication Monitor on Twitter Follow APhA Druginfoline on Twitter

2215 Constitution Avenue NW, Washington, DC 20037 Telephone 202-628-4410 Fax 202-783-2351

© 2013 American Pharmacists Association All Rights Reserved.

About the American
Pharmacists Association

The American Pharmacists Association (APhA) is the organization whose members are recognized in society as essential in all patient care settings for optimal medication use that improves health, wellness and quality of life. Through information, education and advocacy, APhA empowers its members to improve medication use and advance patient care.

About APhA DrugInfoLine

APhA DrugInfoLine (ISSN 2162-3015) is a weekly publication of, and is owned and copyrighted by the American Pharmacists Association, the national professional society of pharmacists. Materials in APhA DrugInfoLine do not neccessarily represent the policy, recommendations, or endorsement of APhA. The publisher, authors, editors, reviewers, and contributors have taken care to ensure that the information contained in APhA DrugInfoLine is accurate and current; however, they shall have no ability to any person or entity with regard to claims, losses, or damage caused or alleged to be caused, directly or indirectly by use of any information contained in the publication. All decisions about drug therapy must be based on independent judgement of the clinician.